Department of Neurology, Mitsui Memorial Hospital, Japan.
Department of Neurology, Tohoku University Graduate School of Medicine, Japan.
Intern Med. 2022 Feb 1;61(3):429-432. doi: 10.2169/internalmedicine.7599-21. Epub 2021 Aug 6.
Optic neuritis (ON) is a rare complication of tumor necrosis factor (TNF)-α inhibitors. The autoantibody serostatus, treatment, and outcome of TNF-α inhibitor-associated ON remain unclear. We herein report a 50-year-old woman with ON following adalimumab therapy. The patient presented with decreasing visual acuity of the right eye, quickly diminishing to light perception. Anti-aquaporin-4 (anti-AQP4) and anti-myelin oligodendrocyte glycoprotein antibodies were negative. Adalimumab was discontinued, and intravenous methylprednisolone and intravenous immunoglobulin (IVIg) were administered. However, her visual acuity improved only up to counting fingers. IVIg may be ineffective depending on the pretreatment severity.
视神经炎（ON）是肿瘤坏死因子（TNF）-α抑制剂的罕见并发症。TNF-α抑制剂相关的视神经炎的自身抗体血清状态、治疗和结局仍不清楚。本文报告了一例阿达木单抗治疗后发生视神经炎的 50 岁女性患者。患者右眼视力下降，迅速降至光感。抗水通道蛋白-4（anti-AQP4）和抗髓鞘少突胶质细胞糖蛋白抗体均为阴性。停用阿达木单抗，给予静脉注射甲基泼尼松龙和静脉注射免疫球蛋白（IVIg）。然而，她的视力仅提高到能数手指。IVIg 的疗效可能取决于预处理的严重程度。
